Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin

Supportive Care in Cancer

Volumn 4, Issue 4, 1996, Pages 313-316

  Lissoni, P ^a   Pittalis, S ^a   Ardizzoia, A ^a   Brivio, F ^a   Barni, S ^a   Tancini, G ^a   Pelizzoni, F ^b   Maestroni, G J M ^c   Zubelewicz, B ^d   Braczkowski, R ^d  

^a SAN GERARDO HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c INSTITUTE OF PATHOLOGY   (Switzerland)

^d Division of Internal Medicine   (Poland)

Author keywords

Hypotension; Immunotherapy; Interleukin 2; Melatonin; Nitric oxide; Tumour necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 2; MELATONIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; HYPOTENSION; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOTENSION; INTERLEUKIN-2; MALE; MELATONIN; MIDDLE AGED; NEOPLASMS; NITRIC OXIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030186555     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01358887     Document Type: Article

References (12)

1. Alleva DG, Burger CJ, Eigen KD (1994) Tumour-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. J Immunol 153:1674-1686
2. Atzpodien J, Kirchner H (1990) Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68:1-11
3. Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379-385
4. Epstein FH (1993) The L-arginine-nitric oxide pathway. N Engl J Med 329:2000-2012
5. Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49:1621-1639
6. Lissoni P, Tisi E, Brivio F, et al (1991) Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeostatic Agents 5:154-156
7. Lissoni P, Barni S, Tancini G, et al (1994) A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196-199
8. Maestroni GJM, Conti A, Pierpaoli W (1986) Role of the pineal gland in immunity. J Neuroimmunol 13:19-26
9. Regelson W, Pierpaoli W (1987) Melatonin: a rediscovered antitumor hormone? Cancer Invest 5:379-385
10. Reiter RJ (1980) The pineal gland: a regulator of regulators. Prog Psychobiol Physiol Psychol 9:323-356
11. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199
12. Spessert R, Hill G, Layes E, Vollrath L (1994) Adrenoceptor stimulation induces nitric oxide formation in rat pinealocytes. Acta Neurobiol Exp 54 [Suppl]: 97-98